Download PDF
J Pediatr Infect Dis 2024; 19(02): 116-121
DOI: 10.1055/s-0044-1778699
Original Article

Late Respiratory and Laboratory Findings in Children with a History of Symptomatic and Asymptomatic SARS-CoV-2 Infection

Ayşe Gul Yucel
1   Department of Pediatrics, Konya City Hospital, Konya, Turkey
,
Ugur Cem Mete
1   Department of Pediatrics, Konya City Hospital, Konya, Turkey
,
Fatma Duksal 
2   Department of Pediatric Allergy and Immunology, Konya City Hospital, Konya, Turkey
› Author Affiliations Funding None.
› Further Information
Also available at
    Permissions and Reprints

Abstract

Objective Symptoms due to coronavirus disease 2019 (COVID-19) may persist or new symptoms may appear later. It was aimed to investigate the relationships between late respiratory system findings, allergen sensitivity, and laboratory findings in children with asymptomatic or symptomatic COVID-19 history.

Methods The study was conducted in tertiary hospital prospectively between April and July 2021. Children with respiratory system symptoms lasting longer than 1 month, with a history of asymptomatic or symptomatic COVID-19 infection and those who were anti-severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)- antibody-positive were included. Late respiratory system findings, allergen sensitivity, and immunological and hematological findings were evaluated. Children with chronic diseases and those who were anti-SARS-CoV-2 antibody-negative were excluded.

Results Of 105 patients, 44.8% were female with a mean age of 10.7 (1–17) years. Median time from history or exposure to COVID-19 was 5 months in all patients. Post-COVID-19 respiratory symptoms were cough (61%), followed by shortness of breath (46.7%), and chest pain (21%), which were similar between symptomatic and asymptomatic patients (p > 0.05). Of the laboratory findings, only the hemoglobin value was significantly higher in symptomatic patients than in asymptomatic patients (p = 0.03), and there was no difference between them in terms of other parameters.

Conclusion It was shown that respiratory system symptoms may occur in the late period after COVID-19. The atopic status and laboratory findings of the patients did not affect this result.

Keywords

atopy - children - COVID-19 - laboratory - respiratory

Authors' Contribution

F.D. and A.G.Y. conceived and designed the evaluation and drafted the manuscript. U.C.M participated in designing, evaluation, performed parts of the statistical analysis and helped to draft the manuscript. All authors collected the clinical data, interpreted them and revised. read and approved the final manuscript.


The work was carried out at Konya City Hospital, Konya, Turkey.




Publication History

Received: 04 October 2023

Accepted: 20 December 2023

Article published online:
04 March 2024

© 2024. Thieme. All rights reserved.

Georg Thieme Verlag KG
Rüdigerstraße 14, 70469 Stuttgart, Germany

 

  • References

  • 1 Nascimento WLCD, Moura DM, Almeida KO, Gomes-Neto M, Jezler SFO, Alves IGN. Lung and physical function in post COVID-19 and clinical and functional associations: cross-sectional study in Brazil. Rev Assoc Med Bras (1992) 2023; 69: e20221436
    CrossrefPubMedGoogle Scholar
  • 2 Buonsenso D, Pujol FE, Munblit D, Pata D, McFarland S, Simpson FK. Clinical characteristics, activity levels and mental health problems in children with long coronavirus disease: a survey of 510 children. Future Microbiol 2022; 17 (08) 577-588
    CrossrefPubMedGoogle Scholar
  • 3 Petroianu A. COVID-19 recurrence associated with the virus storage in the spleen. Rev Assoc Med Bras 2022; 68 (06) 751-753
    CrossrefPubMedGoogle Scholar
  • 4 Mizrahi B, Sudry T, Flaks-Manov N. et al. Long covid outcomes at one year after mild SARS-CoV-2 infection: nationwide cohort study. BMJ 2023; 380: e072529
    CrossrefPubMedGoogle Scholar
  • 5 Bogiatzopoulou A, Mayberry H, Hawcutt DB. et al. COVID-19 in children: what did we learn from the first wave?. Paediatr Child Health (Oxford) 2020; 30 (12) 438-443
    CrossrefPubMedGoogle Scholar
  • 6 Munblit D, Simpson F, Mabbitt J, Dunn-Galvin A, Semple C, Warner JO. Legacy of COVID-19 infection in children: long-COVID will have a lifelong health/economic impact. Arch Dis Child 2022; 107 (03) e2
    CrossrefPubMedGoogle Scholar
  • 7 Zavala M, Ireland G, Amin-Chowdhury Z, Ramsay ME, Ladhani SN. Acute and persistent symptoms in children with polymerase chain reaction (PCR)-confirmed severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection compared with test-negative children in England: active, prospective, national surveillance. Clin Infect Dis 2022; 75 (01) e191-e200
    CrossrefPubMedGoogle Scholar
  • 8 Dong Y, Mo X, Hu Y. et al. Epidemiology of COVID-19 among children in China. Pediatrics 2020; 145 (06) e20200702
    CrossrefPubMedGoogle Scholar
  • 9 Buonsenso D, Munblit D, De Rose C. et al. Preliminary evidence on long COVID in children. Acta Paediatr 2021; 110 (07) 2208-2211
    CrossrefPubMedGoogle Scholar
  • 10 Zhao YM, Shang YM, Song WB. et al. Follow-up study of the pulmonary function and related physiological characteristics of COVID-19 survivors three months after recovery. EClinicalMedicine 2020; 25: 100463
    CrossrefPubMedGoogle Scholar
  • 11 Esmaeilzadeh H, Sanaei Dashti A, Mortazavi N, Fatemian H, Vali M. Persistent cough and asthma-like symptoms post COVID-19 hospitalization in children. BMC Infect Dis 2022; 22 (01) 244
    CrossrefPubMedGoogle Scholar
  • 12 Knoke L, Schlegtendal A, Maier C, Eitner L, Lücke T, Brinkmann F. Pulmonary function and long-term respiratory symptoms in children and adolescents after COVID-19. Front Pediatr 2022; 10: 851008
    CrossrefPubMedGoogle Scholar
  • 13 Cavalcante Pinto Júnior V, Moura LFWG, Cavalcante RC. et al. Prevalence of COVID-19 in children, adolescents and adults in remote education situations in the city of Fortaleza, Brazil. Int J Infect Dis 2021; 108: 20-26
    CrossrefPubMedGoogle Scholar
  • 14 Wang J, Tang Y, Ma Y. et al; COVID-19 Evidence and Recommendations Working Group. Efficacy and safety of antibiotic agents in children with COVID-19: a rapid review. Ann Transl Med 2020; 8 (10) 619
    CrossrefPubMedGoogle Scholar
  • 15 Wang D, Ju XL, Xie F. et al. [Clinical analysis of 31 cases of 2019 novel coronavirus infection in children from six provinces (autonomous region) of northern China]. Zhonghua Er Ke Za Zhi 2020; 58 (04) 269-274
    PubMedGoogle Scholar
  • 16 Ramakrishnan S, Nicolau Jr DV, Langford B. et al. Inhaled budesonide in the treatment of early COVID-19 (STOIC): a phase 2, open-label, randomised controlled trial. Lancet Respir Med 2021; 9 (07) 763-772
    CrossrefPubMedGoogle Scholar
  • 17 Al Khoufi E, Al-Muhainy B, Algadeeb K, Alsalman M. Autoimmune hemolytic anemia: a late presentation of post-COVID-19 syndrome. Oman Med J 2023; 38 (01) e467
    CrossrefPubMedGoogle Scholar
  • 18 Koseoglu HI, Altunkas F, Kanbay A, Doruk S, Etikan I, Demir O. Platelet-lymphocyte ratio is an independent predictor for cardiovascular disease in obstructive sleep apnea syndrome. J Thromb Thrombolysis 2015; 39 (02) 179-185
    CrossrefPubMedGoogle Scholar
  • 19 Yu S, Arima H, Bertmar C, Clarke S, Herkes G, Krause M. Neutrophil to lymphocyte ratio and early clinical outcomes in patients with acute ischemic stroke. J Neurol Sci 2018; 387: 115-118
    CrossrefPubMedGoogle Scholar
  • 20 Pollán M, Pérez-Gómez B, Pastor-Barriuso R. et al; ENE-COVID Study Group. Prevalence of SARS-CoV-2 in Spain (ENE-COVID): a nationwide, population-based seroepidemiological study. Lancet 2020; 396 (10250): 535-544
    CrossrefPubMedGoogle Scholar
  • 21 Ibrahim ZH, Al-Diwan JK. The association between COVID-19 and atopy in Baghdad, Iraq, 2022. Med J Malaysia 2023; 78 (06) 717-720
    PubMedGoogle Scholar
  • 22 Timberlake DT, Narayanan D, Ogbogu PU. et al. Severity of COVID-19 in hospitalized patients with and without atopic disease. World Allergy Organ J 2021; 14 (02) 100508
    CrossrefPubMedGoogle Scholar
  • 23 Du H, Dong X, Zhang JJ. et al. Clinical characteristics of 182 pediatric COVID-19 patients with different severities and allergic status. Allergy 2021; 76 (02) 510-532
    CrossrefPubMedGoogle Scholar
  • 24 Brodin P. Immune determinants of COVID-19 disease presentation and severity. Nat Med 2021; 27 (01) 28-33
    CrossrefPubMedGoogle Scholar
  • 25 Guan WJ, Liang WH, Zhao Y. et al; China Medical Treatment Expert Group for COVID-19. Comorbidity and its impact on 1590 patients with COVID-19 in China: a nationwide analysis. Eur Respir J 2020; 55 (05) 2000547
    CrossrefPubMedGoogle Scholar